The ESRG Group announces an investment in groundbreaking medical diagnostics company Biosignatures

The ESRG Group announces another addition to its extensive investment portfolio, having secured an agreement to invest in groundbreaking medical diagnostics company Biosignatures.

Biosignatures is set to lead the way using a pioneering method of medical testing, with analysis through its unique patented software platform, Tiger. Testing is minimally invasive – for example allowing the replacement of a biopsy with a simple blood test, is cost effective, and ideally suited for today’s medical sector. The Biosignatures systems are adaptable and relevant to a range of needs and procedures; they can be applied to both prognostic testing and diagnostics.

Biosignatures was established in 2007, as an offshoot from Nonlinear Dynamics Ltd, and led by the same directorship team; Will Dracup CEO, Dave Bramwell CTO, and Duncan Barrie FD. Will Dracup has 27 years computing experience, founding Nonlinear in 1989, creating the initial products and leading it throughout its 25 year history. Duncan Barrie is a Chartered Accountant and Fellow of the Securities Institute, with over 23 years experience in high-end companies. Dr David Bramwell has 21 years computing experience, including postdoctoral work on human neural systems. Joining Nonlinear in 2000, David and his research team designed Nonlinear’s flagship analysis product Progenesis™ (launched April 2001) and created the Company’s Tiger Technology and MPM platforms.

The ESRG Group funding will initially be channelled towards clinical trials of the Biosignatures product, to facilitate company expansion through marketing existing products whilst simultaneously directing investment into the development of new ones. Biosignatures has secured a major commercial agreement with the Newcastle upon Tyne Healthcare Foundation Trust – a major part of the NHS, and one of the biggest clinical research organisations in the UK. The company is also actively building relationships with prominent US corporations.

Speaking on behalf of the ESRG Group, David Evans CEO explained that “Biosignatures has a groundbreaking concept, the technical knowledge to push it forward within the industry, and the business tenacity to guarantee success. The ESRG Group involvement is both a privilege and a sound financial investment, and we look forward to working together with the Biosignatures directors to ensure it reaches its maximum potential”.